Business Context and Reporting Period
This Form 8-K Current Report was filed by Lyell Immunopharma, Inc. on September 29, 2021. The filing addresses corporate governance changes involving the Board of Directors and provides updates on the company's research and development timeline.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on personnel changes and forward-looking operational expectations.
Material Changes
- Executive Departure: Dr. Richard Klausner, Chair of the Board and Executive Chairman, announced a temporary medical leave of absence effective September 29, 2021.
- Role Resignation: Dr. Klausner will resign as Executive Chairman and cease to be an employee effective October 1, 2022, though he will retain his position as Chair of the Board.
- Interim Leadership: The Board elected Cathy Friedman, the lead independent director, to serve as interim Chair of the Board during Dr. Klausner's absence.
Guidance, Outlook, and Risks
Operational Outlook: Management does not anticipate the leave will impact the company's timelines for investigational new drug (IND) applications, research and development progress, or corporate objectives. The company continues to expect to submit four INDs to the FDA by the end of 2022.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Actual results may vary due to risks detailed in the company's Form 10-Q for the quarter ended June 30, 2021, including uncertainties regarding the duration of Dr. Klausner's leave and the timing of his return.
Key Facts for Investor Verification
- Dr. Klausner's expected return date is early 2022.
- Cathy Friedman has been appointed interim Chair of the Board.
- The company maintains its target of submitting four INDs to the FDA by the end of 2022.
- Dr. Klausner will remain on the Board as Chair despite resigning as Executive Chairman and employee.